Lamivudine Teva Pharma B.V (Lamivudine)

After oral administration, lamivudine is taken up by cells and phosphorylated to its active triphosphate form. This metabolite mimics natural nucleosides and is incorporated by viral reverse transcriptase, causing premature termination of the viral DNA chain and thereby inhibiting replication of HIV and hepatitis B virus.

The specific dose of lamivudine is determined by the prescribing healthcare professional based on the patient’s condition, weight, renal function, and other clinical factors. Patients should follow the dosage instructions provided by their prescriber and not adjust the dose on their own.

The safety of lamivudine in pregnancy and lactation has not been definitively established. It may be prescribed if the potential benefits to the mother outweigh any possible risks to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and benefits with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Lamivudine Teva Pharma B.V. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class, offering a favorable safety profile and convenient once‑daily dosing when combined with other agents. Compared with some older NRTIs, it has lower mitochondrial toxicity and fewer metabolic side effects, making it a common component of modern combination regimens.

Lamivudine tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Do not store in areas with high humidity or extreme temperatures, and keep out of reach of children.

Lamivudine is taken orally, usually with or without food, as a tablet that is swallowed whole with water. The exact administration schedule—once daily or divided doses—depends on the prescribing regimen and should be followed as directed by the healthcare professional.

Serious adverse events, although rare, include lactic acidosis, severe hepatomegaly with steatosis, pancreatitis, severe skin reactions such as Stevens‑Johnson syndrome, hypersensitivity reactions, and significant neutropenia. Patients should seek immediate medical attention if they experience symptoms such as unexplained fatigue, abdominal pain, rapid breathing, or skin rash.

Lamivudine is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is also advised for individuals with severe renal impairment, active liver disease, or those taking medications that have major interaction potential, unless close monitoring is possible.